Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 19844714)

1.

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.

Greene DP, Ferriss JS, Jazaeri AA.

Cancer Chemother Pharmacol. 2010 Jul;66(2):265-7. doi: 10.1007/s00280-009-1159-6. Epub 2009 Oct 21.

PMID:
19844714
2.

Platinum hypersensitivity and desensitization.

Miyamoto S, Okada R, Ando K.

Jpn J Clin Oncol. 2015 Jun 7. pii: hyv081. [Epub ahead of print] Review.

PMID:
26056327
3.

[Ovarian cancer: TC therapy].

Sugano T, Katsumata N.

Nihon Rinsho. 2015 Feb;73 Suppl 2:604-8. Japanese. No abstract available.

PMID:
25831831
4.

Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.

Li Q, Cohn D, Waller A, Backes F, Copeland L, Fowler J, Salani R, O'Malley D.

Gynecol Oncol. 2014 Oct;135(1):90-4. doi: 10.1016/j.ygyno.2014.07.104. Epub 2014 Aug 7.

PMID:
25110329
5.

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.

van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, Kerkhofs LG, Valster FA, Ruit JB, van Reisen AG, Goey SH, van der Torren AM, ten Bokkel Huinink D, Kok TC, Verweij J, van Doorn HC.

Eur J Cancer. 2014 Oct;50(15):2592-601. doi: 10.1016/j.ejca.2014.07.015. Epub 2014 Aug 2.

PMID:
25096168
6.

4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.

Takase N, Matsumoto K, Onoe T, Kitao A, Tanioka M, Kikukawa Y, Yamaguchi S, Fujiwara K, Negoro S.

Int J Clin Oncol. 2015 Jun;20(3):566-73. doi: 10.1007/s10147-014-0731-1. Epub 2014 Jul 18.

PMID:
25030546
7.

Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.

Taylor SE, Beck TL, Krivak TC, Zorn KK, Kelley JL, Edwards RP.

Gynecol Oncol. 2014 Jul;134(1):68-72. doi: 10.1016/j.ygyno.2014.04.039. Epub 2014 Apr 24.

PMID:
24769036
8.
9.

Increasing the chances for platinum-sensitive ovarian cancer patients.

González A.

Future Oncol. 2013 Dec;9(12 Suppl):29-35. doi: 10.2217/fon.13.204. Review.

PMID:
24195528
10.

The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.

Safra T, Asna N, Veizman A, Shpigel S, Matcejevsky D, Inbar M, Grisaru D.

Anticancer Drugs. 2014 Mar;25(3):340-5. doi: 10.1097/CAD.0000000000000042.

PMID:
24185383
11.

The retreatment of carboplatin via high-dose intraperitoneal chemotherapy in patients with a history of a hypersensitivity reaction.

Rettenmaier MA, Gray CM, Lopez KL, Bechtol KA, Goldstein BH.

Am J Obstet Gynecol. 2014 Feb;210(2):e1-2. doi: 10.1016/j.ajog.2013.10.883. Epub 2013 Nov 1.

PMID:
24184183
12.
13.

A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.

Abaid LN, Micha JP, Rettenmaier MA, Brown JV, Mendivil AA, Lopez KL, Goldstein BH.

Cancer Chemother Pharmacol. 2013 Jul;72(1):101-7. doi: 10.1007/s00280-013-2173-2. Epub 2013 May 10.

PMID:
23660691
14.

Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin.

Arimoto T, Oda K, Nakagawa S, Kawana K, Tsukazaki T, Adachi K, Matsumoto Y, Yano T, Kozuma S, Taketani Y.

J Obstet Gynaecol Res. 2013 Jan;39(1):336-40. doi: 10.1111/j.1447-0756.2012.01917.x. Epub 2012 Jun 13.

PMID:
22690725
15.

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.

Gynecol Oncol. 2012 Sep;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028. Epub 2012 May 30.

PMID:
22659190
16.

Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies.

Tamiya M, Kuhara H, Hirashima T, Kondo Y, Santo M, Morishita N, Suzuki H, Sasada S, Okamoto N, Kobayashi M, Kawase I.

Anticancer Res. 2011 Dec;31(12):4525-8.

PMID:
22199326
17.
18.

A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.

Sehouli J, Alvarez AM, Manouchehrpour S, Ghatage P, Szczylik C, Zimmermann A, Bauknecht T, Look KY, Oskay-Öezcelik G.

Gynecol Oncol. 2012 Feb;124(2):205-9. doi: 10.1016/j.ygyno.2011.09.007. Epub 2011 Nov 1.

PMID:
22044606
20.

Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.

Kelly MG, Mor G, Husband A, O'Malley DM, Baker L, Azodi M, Schwartz PE, Rutherford TJ.

Int J Gynecol Cancer. 2011 May;21(4):633-9. doi: 10.1097/IGC.0b013e3182126f05.

PMID:
21412168
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk